港大與中大研究倡以mRNA核酸疫苗為加強劑應對Omicron
香港大學與中文大學的聯合研究顯示,為民眾接種科興新冠疫苗的國家及地區,應考慮以mRNA核酸疫苗作為加強劑,來產生較好的中和抗體水平,以應對變種病毒株Omicron擴散。
研究團隊指,與原始病毒株比較,不論接種兩劑科興或復必泰疫苗,三至五個星期後,應對Omicron的血清抗體水平均顯著下降。該研究發現,80%至85%接種復必泰作為第三針加強劑的人士,抗體水平足以抵禦Omicron;但接種三劑科興,或者早前曾受感染的人士,就只有3%能誘發足夠抗體水平。 有關研究已經刊登在《自然》醫學期刊。
不過研究人員提醒,早前已證實接種科興疫苗,能刺激人體產生T細胞反應,可解決中和抗體保護力下降的問題,目前仍然急需研究接種不同平台疫苗的有效性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.